Introduction. Osteoporosis is a long-term bone disease that causes a gradual loss of bone density and weakens its internal structure, increasing the risk of bone fractures. Prior preclinical studies have demonstrated that Sigma Anti-bonding Molecule Calcium Carbonate (SAC) exhibits beneficial effects on bone integrity in ovariectomized rat models. This clinical investigation evaluates the impact of SAC supplementation on bone mineral density(BMD) in an Asian cohort. Methods. A total of 82 participants were enrolled and stratified into three groups based on T-score: normal bone density (n=18), osteopenia (n=31), and osteoporosis (n=33). T-scores, BMD, and speed of sound (SOS) were measured at baseline and following approximately eight months of SAC intervention. All measurements were conducted at the distal radius, a clinically relevant site for assessing peripheral bone density. Results. After SAC administration, T-scores improved significantly (from -2.0 to -0.85, p<0.0001) along with increased BMD (from 0.95 to 1.10 g/cm², p<0.0001) across all age and gender groups. SAC treatment also significantly increased SOS values from 3,946 to 4,079 (p < 0.0001). Further, 65% of participants with osteopenia (20/31) improved to the normal group after treatment, while 64% of participants with osteoporosis (21/33) were reclassified into the osteopenia group. Remarkably, 12% of participants with baseline osteoporosis (4/33) transitioned into the normal bone density range. Discussion. Our findings suggest that SAC supplementation leads to significant improvements in bone health in Asian individuals, a population with higher susceptibility to osteoporosis. These results indicate that SAC could be a useful option to slow down age-related bone loss.